文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

择期腹部大手术围术期药物血栓预防的最佳时机:系统综述与Meta分析

Optimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis.
PubMed 文献 · Ann Surg · 2022-11-24

该系统综述与Meta分析纳入14项研究共24,922例择期腹部大手术患者,比较皮肤闭合前与术后启动药物血栓预防对静脉血栓栓塞症(VTE)和出血的影响。结果显示两组症状性及总体VTE风险相当,但早期(皮肤闭合前)启动显著增加所有出血、大出血、输血和再干预风险。结论支持择期腹部手术术后启动药物血栓预防,以在不影响VTE保护的前提下减少出血风险。

要点

  • 择期腹部大手术中,皮肤闭合前与术后启动药物血栓预防的VTE风险相当。
  • 早期启动药物血栓预防显著增加所有出血、大出血、输血和再干预风险。
  • 建议择期腹部大手术后启动药物血栓预防,以平衡VTE预防与出血风险。

核心结论

  • 择期腹部大手术术后启动药物血栓预防可减少出血风险而不影响VTE保护。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、Cochrane Library和Web of Science,纳入2000年1月1日至2022年5月10日发表的随机试验和队列研究,最终分析14项研究共24,922例患者。

主要发现

  • 皮肤闭合前启动药物血栓预防的患者10,403例,术后启动者14,519例。
  • 两组症状性VTE风险相当(RR 0.81,95%CI 0.45-1.43,P=0.460)。
  • 两组总体VTE风险相当(RR 0.74,95%CI 0.45-1.24,P=0.250)。
  • 与术后启动相比,早期启动增加所有出血风险(RR 1.56,95%CI 1.13-2.15,P=0.007)。
  • 早期启动增加大出血(RR 1.63,95%CI 1.16-2.28,P=0.005)、输血(RR 1.48,95%CI 1.24-1.76,P<0.001)和再干预(RR 1.94,95%CI 1.19-3.18,P=0.008)风险。

临床怎么用

  • 择期腹部大手术患者可考虑术后启动药物血栓预防,以降低出血及相关并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of the timing of chemoprophylaxis on venous thromboembolisms (VTEs) and bleeding rates in patients undergoing major abdominal surgery. BACKGROUND: Postoperative bleeding and VTE incur significant morbidity, mortality, and health care costs. Chemoprophylaxis is used routinely to prevent VTEs but increases bleeding risk. The perioperative timing of chemoprophylaxis initiation may influence both VTE and bleeding risks. The optimal window for commencing chemoprophylaxis in the perioperative period is unclear. METHODS: MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were searched using PRISMA guidelines. Randomized trials and cohort studies published between January 1, 2000 to May 10, 2022, which reported on chemoprophylaxis timing as well as the incidence of VTE and bleeding after elective abdominal surgery were meta-analyzed. RESULTS: From 6175 studies, 14 (24,922 patients) were meta-analyzed. Bariatric (4 studies), antireflux (1 study), hepato-pancreatic-biliary (5 studies), colorectal (1 study), ventral hernia (1 study), and major intra-abdominal surgeries (2 studies) were included. Chemoprophylaxis was initiated before skin closure in 10,403 patients, and postoperatively in 14,519 patients. Both symptomatic [risk ratios (RR), 0.81; 95% CI, 0.45-1.43; P =0.460] and overall (RR, 0.74; 95% CI, 0.45-1.24; P =0.250) VTE rates were comparable between study groups. Compared with postoperative chemoprophylaxis, early usage increased the risk of all bleeding (RR, 1.56; 95% CI, 1.13-2.15; P =0.007), major bleeding (RR, 1.63; 95% CI, 1.16-2.28; P =0.005), blood transfusion (RR, 1.48; 95% CI, 1.24-1.76; P <0.001), and reintervention (RR, 1.94; 95% CI, 1.19-3.18; P =0.008). CONCLUSIONS: Our findings advocate for initiating chemoprophylaxis postoperatively in elective abdominal surgery to minimize bleeding risk without compromising VTE protection.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Klonis C, Ashraf H, Cabalag CS, et al. Optimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis. Ann Surg. 2022. PMID: 36538616. doi:10.1097/SLA.0000000000005764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。